FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2069308519> ?p ?o ?g. }

• W2069308519 endingPage "1255" @default.
• W2069308519 startingPage "1246" @default.
• W2069308519 abstract "The histologic distinction between high-grade prostate cancer and infiltrating high-grade urothelial cancer may be difficult, and has significant implications because each disease may be treated very differently (ie, hormone therapy for prostate cancer and chemotherapy for urothelial cancer). Immunohistochemistry of novel and established prostatic and urothelial markers using tissue microarrays (TMAs) were studied. Prostatic markers studied included: prostate-specific antigen (PSA), prostein (P501s), prostate-specific membrane antigen (PSMA), NKX3.1 (an androgen-related tumor suppressor gene), and proPSA (pPSA) (precursor form of PSA). “Urothelial markers” included high molecular weight cytokeratin (HMWCK), p63, thrombomodulin, and S100P (placental S100). TMAs contained 38 poorly differentiated prostate cancers [Gleason score 8 (n=2), Gleason score 9 (n=18), Gleason score 10 (n=18)] and 35 high-grade invasive urothelial carcinomas from radical prostatectomy and cystectomy specimens, respectively. Each case had 2 to 8 tissue spots (0.6-mm diameter). If all spots for a case showed negative staining, the case was called negative. The sensitivities for labeling prostate cancers were PSA (97.4%), P501S (100%), PSMA (92.1%), NKX3.1 (94.7%), and pPSA (94.7%). Because of PSA's high sensitivity on the TMA, we chose 41 additional poorly differentiated primary (N=36) and metastatic (N=5) prostate carcinomas which showed variable PSA staining at the time of diagnosis and performed immunohistochemistry on routine tissue sections. Compared to PSA, which on average showed 18.8% of cells with moderate to strong positivity, cases stained for P501S, PSMA, and NKX3.1 had on average 42.5%, 53.7%, 52.9% immunoreactivity, respectively. All prostatic markers showed excellent specificity. HMWCK, p63, thrombomodulin, and S100P showed lower sensitivities in labeling high-grade invasive urothelial cancer in the TMAs with 91.4%, 82.9%, 68.6%, and 71.4% staining, respectively. These urothelial markers were relatively specific with only a few prostate cancers showing scattered (≤2%) weak-moderate positive cells. In summary, PSA can be used as the first screening marker for differentiating high-grade prostate adenocarcinoma from high-grade urothelial carcinoma. Immunohistochemistry for P501S, PSMA, NKX3.1, and pPSA are useful when high-grade prostate cancer is suspected based on the morphology or clinical findings, yet shows negative or equivocal PSA staining. HMWCK and p63 are superior to the novel markers thrombomodulin and S100P." @default.
• W2069308519 created "2016-06-24" @default.
• W2069308519 creator A5009195048 @default.
• W2069308519 creator A5034550469 @default.
• W2069308519 creator A5048881491 @default.
• W2069308519 creator A5049793329 @default.
• W2069308519 creator A5062227791 @default.
• W2069308519 creator A5073431093 @default.
• W2069308519 date "2007-08-01" @default.
• W2069308519 modified "2023-10-18" @default.
• W2069308519 title "Immunohistochemical Differentiation of High-grade Prostate Carcinoma From Urothelial Carcinoma" @default.
• W2069308519 cites W147570767 @default.
• W2069308519 cites W1566315211 @default.
• W2069308519 cites W1931112833 @default.
• W2069308519 cites W1966517939 @default.
• W2069308519 cites W1969453424 @default.
• W2069308519 cites W1974940609 @default.
• W2069308519 cites W1982232468 @default.
• W2069308519 cites W1994550088 @default.
• W2069308519 cites W1996722997 @default.
• W2069308519 cites W1997715784 @default.
• W2069308519 cites W1999070529 @default.
• W2069308519 cites W1999678872 @default.
• W2069308519 cites W2001597212 @default.
• W2069308519 cites W2003579486 @default.
• W2069308519 cites W2023862781 @default.
• W2069308519 cites W2032696295 @default.
• W2069308519 cites W2053554578 @default.
• W2069308519 cites W2058815669 @default.
• W2069308519 cites W2073911213 @default.
• W2069308519 cites W2082673527 @default.
• W2069308519 cites W2127625592 @default.
• W2069308519 cites W2128019596 @default.
• W2069308519 cites W2147136637 @default.
• W2069308519 cites W2163470211 @default.
• W2069308519 cites W2169261424 @default.
• W2069308519 cites W64304463 @default.
• W2069308519 doi "https://doi.org/10.1097/pas.0b013e31802f5d33" @default.
• W2069308519 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17667550" @default.
• W2069308519 hasPublicationYear "2007" @default.
• W2069308519 type Work @default.
• W2069308519 sameAs 2069308519 @default.
• W2069308519 citedByCount "180" @default.
• W2069308519 countsByYear W20693085192012 @default.
• W2069308519 countsByYear W20693085192013 @default.
• W2069308519 countsByYear W20693085192014 @default.
• W2069308519 countsByYear W20693085192015 @default.
• W2069308519 countsByYear W20693085192016 @default.
• W2069308519 countsByYear W20693085192017 @default.
• W2069308519 countsByYear W20693085192018 @default.
• W2069308519 countsByYear W20693085192019 @default.
• W2069308519 countsByYear W20693085192020 @default.
• W2069308519 countsByYear W20693085192021 @default.
• W2069308519 countsByYear W20693085192022 @default.
• W2069308519 countsByYear W20693085192023 @default.
• W2069308519 crossrefType "journal-article" @default.
• W2069308519 hasAuthorship W2069308519A5009195048 @default.
• W2069308519 hasAuthorship W2069308519A5034550469 @default.
• W2069308519 hasAuthorship W2069308519A5048881491 @default.
• W2069308519 hasAuthorship W2069308519A5049793329 @default.
• W2069308519 hasAuthorship W2069308519A5062227791 @default.
• W2069308519 hasAuthorship W2069308519A5073431093 @default.
• W2069308519 hasConcept C121608353 @default.
• W2069308519 hasConcept C126322002 @default.
• W2069308519 hasConcept C126894567 @default.
• W2069308519 hasConcept C142724271 @default.
• W2069308519 hasConcept C193270364 @default.
• W2069308519 hasConcept C204232928 @default.
• W2069308519 hasConcept C2776235491 @default.
• W2069308519 hasConcept C2777546739 @default.
• W2069308519 hasConcept C2779012181 @default.
• W2069308519 hasConcept C2779466945 @default.
• W2069308519 hasConcept C2780192828 @default.
• W2069308519 hasConcept C2781406297 @default.
• W2069308519 hasConcept C71924100 @default.
• W2069308519 hasConcept C87874733 @default.
• W2069308519 hasConceptScore W2069308519C121608353 @default.
• W2069308519 hasConceptScore W2069308519C126322002 @default.
• W2069308519 hasConceptScore W2069308519C126894567 @default.
• W2069308519 hasConceptScore W2069308519C142724271 @default.
• W2069308519 hasConceptScore W2069308519C193270364 @default.
• W2069308519 hasConceptScore W2069308519C204232928 @default.
• W2069308519 hasConceptScore W2069308519C2776235491 @default.
• W2069308519 hasConceptScore W2069308519C2777546739 @default.
• W2069308519 hasConceptScore W2069308519C2779012181 @default.
• W2069308519 hasConceptScore W2069308519C2779466945 @default.
• W2069308519 hasConceptScore W2069308519C2780192828 @default.
• W2069308519 hasConceptScore W2069308519C2781406297 @default.
• W2069308519 hasConceptScore W2069308519C71924100 @default.
• W2069308519 hasConceptScore W2069308519C87874733 @default.
• W2069308519 hasIssue "8" @default.
• W2069308519 hasLocation W20693085191 @default.
• W2069308519 hasLocation W20693085192 @default.
• W2069308519 hasOpenAccess W2069308519 @default.
• W2069308519 hasPrimaryLocation W20693085191 @default.
• W2069308519 hasRelatedWork W1888477076 @default.
• W2069308519 hasRelatedWork W2019921780 @default.
• W2069308519 hasRelatedWork W2032157250 @default.

• next